Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 1
2011 1
2012 4
2013 1
2014 4
2015 5
2016 3
2017 3
2018 3
2019 6
2020 2
2021 3
2022 4
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, Chasnyk VG, Hufnagel M, Żuber Z, Schulert G, Ozen S, Rakhimyanova A, Ramanan A, Scott C, Sozeri B, Zholobova E, Martin R, Zhu X, Whelan S, Pricop L, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Brunner HI, et al. Among authors: zuber z. Ann Rheum Dis. 2023 Jan;82(1):154-160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. Ann Rheum Dis. 2023. PMID: 35961761 Free PMC article. Clinical Trial.
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, Antón J, Wang Z, Meszaros G, Araújo J, Liao R, Keller S, Brunner HI, Ruperto N; JUVE-BASIS investigators; Paediatric Rheumatology International Trials Organisation. Ramanan AV, et al. Lancet. 2023 Aug 12;402(10401):555-570. doi: 10.1016/S0140-6736(23)00921-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423231 Clinical Trial.
Role of Microparticles in the Pathogenesis of Inflammatory Joint Diseases.
Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Żuber Z, Wojtkiewicz M, Wojtkiewicz J. Krajewska-Włodarczyk M, et al. Among authors: zuber z. Int J Mol Sci. 2019 Nov 1;20(21):5453. doi: 10.3390/ijms20215453. Int J Mol Sci. 2019. PMID: 31683793 Free PMC article. Review.
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
Vojinović J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, Stanevicha V, Kobusinska K, Zuber Z, Dobrzyniecka B, Akikusa J, Avcin T, Borlenghi C, Arthur E, Tatulych SY, Zang C, Tsekouras V, Vlahos B, Martini A, Ruperto N. Vojinović J, et al. Among authors: zuber z. Rheumatology (Oxford). 2024 Jan 4;63(1):140-148. doi: 10.1093/rheumatology/kead183. Rheumatology (Oxford). 2024. PMID: 37140539 Clinical Trial.
Rheumatoid arthritis epidemiology: a nationwide study in Poland.
Krajewska-Włodarczyk M, Szeląg M, Batko B, Żuber Z, Orleański M, Podwójcic K, Sowiński J, Jopek J, Świderek M, Maluchnik M, Brzosko M, Śmiglewska A, Kwiatkowska B. Krajewska-Włodarczyk M, et al. Among authors: zuber z. Rheumatol Int. 2024 Apr 27. doi: 10.1007/s00296-024-05591-8. Online ahead of print. Rheumatol Int. 2024. PMID: 38678142
47 results